Leflunomide as a cause of collagenous colitis: an entity to consider

Rev Esp Enferm Dig. 2021 Oct;113(10):735. doi: 10.17235/reed.2021.8015/2021.

Abstract

Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.

Publication types

  • Letter

MeSH terms

  • Antirheumatic Agents* / adverse effects
  • Arthritis, Rheumatoid* / drug therapy
  • Colitis, Collagenous* / chemically induced
  • Colitis, Collagenous* / drug therapy
  • Humans
  • Isoxazoles / adverse effects
  • Leflunomide / therapeutic use

Substances

  • Antirheumatic Agents
  • Isoxazoles
  • Leflunomide